Under development selectivity

Maintenance of conditions ia the culture environment that keep stress to a minimum is one of the best methods of a voiding diseases. Vacciaes have beea developed agaiast several diseases and more are under development. Selective breeding of animals with disease resistance has met with only limited success. Good sanitation and disiafection of contaminated faciUties are important avoidance and control measure. Some disiafectants are Hsted ia Table 6. Poad soils can be sterilized with burnt lime (CaO), hydrated lime [Ca(OH)2], or chlorine compounds (12). 

Under development Selective and nonselective agonists of VPAC1 and VPAC2 receptors Vasodilation multiple metabolic, endocrine, and other effects Type 2 diabetes chronic obstructive pulmonary disease1... 

A similar process to SMDS using an improved catalyst is under development by Norway s state oil company, den norske state oHjeselskap AS (Statod) (46). High synthesis gas conversion per pass and high selectivity to wax are claimed. The process has been studied in bubble columns and a demonstration plant is planned. 

The blanket deposition is then sputter etched through a resist to pattern the metallisation. Selective deposition of W, under development, would deposit metal only in desired areas, and would reduce process steps and costs. 

Redox flow batteries, under development since the early 1970s, are stUl of interest primarily for utility load leveling applications (77). Such a battery is shown schematically in Figure 5. Unlike other batteries, the active materials are not contained within the battery itself but are stored in separate tanks. The reactants each flow into a half-ceU separated one from the other by a selective membrane. An oxidation and reduction electrochemical reaction occurs in each half-ceU to generate current. Examples of this technology include the iron—chromium, Fe—Cr, battery (79) and the vanadium redox cell (80). 

Metal Oxide - Since metals are less electrophilic than silicon, metal oxide adsorbents show even stronger selectivity for polar molecules than do siliceous materials. The most commonly used metal oxide adsorbent is activated alumina, used primarily for gas drying. Occasionally, metal oxides find applications in specific chemisorption systems. For example, several processes are under development utilizing lime or limestone for removal of sulfur oxides from flue gases. Activated aluminas have surface areas in the range of 200 to 1,000 ftVft Average pore diameters range from about 30 to 80 A. 

LY311727 is an indole acetic acid based selective inhibitor of human non-pancreatic secretory phospholipase A2 (hnpsPLA2) under development by Lilly as a potential treatment for sepsis. The synthesis of LY311727 involved a Nenitzescu indolization reaction as a key step. The Nenitzescu condensation of quinone 4 with the p-aminoacrylate 39 was carried out in CH3NO2 to provide the desired 5-hydroxylindole 40 in 83% yield. Protection of the 5-hydroxyl moiety in indole 40 was accomplished in H2O under phase transfer conditions in 80% yield. Lithium aluminum hydride mediated reduction of the ester functional group in 41 provided the alcohol 42 in 78% yield. 

MSA are under development at the NASA s Goddard Space Flight Center, and has been selected to be the multi-slit device for NIRSpec. They use a combination of magnetic effect for shutter opening, and electrostatic effect for shutter latching in the open position (Moseley et al., 2002). 

A crucial issue for antiviral therapy is the fact that all antiviral substances rapidly select for resistance thus, monitoring and overcoming resistance has become a most important clinical paradigm of antiviral therapy. This calls for cautious use of antiviral drugs and implementation of combination therapies. In parallel, efforts in drug discovery have to be continued to develop compounds with novel mode-of-action and activity against resistant strains. This book reviews the current status of antiviral therapy, from the roads to development of new compounds to their clinical use and cost effectiveness. Individual chapters address in more detail all available drug classes and outline new approaches currently under development. 

Validate routine methods, i.e., define the conditions under which the assay results are meaningful.115 To do that, one must select samples that are truly representative of the product stream. This may be a difficult task when the process is still under development and the product stream variable. The linearity of detector response should be defined over a range much broader than that expected to be encountered. Interference from the sample matrix and bias from analyte loss in preparation or separation often can be inferred from studies of linearity. Explicit detection or quantitation limits should be established. The precision (run-to-run repeatability) and accuracy (comparison with known standards) can be estimated with standards. Sample stability should be explored and storage conditions defined. 

Figure 5 shows examples of two dry powder inhalers, the Turbuhaler and the Diskus, currently marketed in the United States for the delivery of the steroids, budesonide and fluticosone, respectively. Table 6 shows the major elements of a number of passive dry powder inhalers. In addition to the commercially available passive inhalation products, a number of active dispersion systems are under development the key characteristics of selected devices are shown in Table 7. 

The next vague of tools will be around computational or in silico ADME approaches. These will allow to include ADME into the design of combinatorial libraries, the evaluation of virtual libraries, as well as in selecting the most promising compounds to go through a battery of in vitro screens, possibly even replacing some of these experimental screens. Several of these computational tools are currently under development as will be discussed in this volume. 

Many of the materials currently under development draw their inspiration from structures found in nature. That is, by mimicking the supramolecular architecture of natural materials, one can prepare complex materials capable of highly sophisticated functions. An important aspect of this work involves the selection of microorganism templates (e.g., diatomite) based on specific porous structures that may benefit targeted applications. 

New treatment options. A variety of new treatment options are currently under development, and may become available in the near future. Among these are transdermal application of short-acting dopamine agonists. Selective D1-receptor agents, such as dihydrexidine also offer promise. In addition, non-dopaminergic treatments are under development. 

A new route with the potential of further lowering PDO cost is the enzymatic fermentation [17, 18] of glycerol and alcohol. This process is still under development by Du Pont and Genecore International. With advances in biogenetic engineering, new strains of engineered bacteria have improved the yield and selectivity of the process to the point where this route is ready for pilot plant scale-up. 

According to one favored theory, mitochondria evolved from aerobic bacteria that were endocytosed by an anaerobic ancestor of eukaryotic cells. The endocytic event is thought to have occurred when oxygen emerged in the atmosphere (about two billion years ago) and threatened most life systems. Under the selective pressure of oxygen, a stable relationship developed in which the host cell had acquired the ability to exploit the bacterial oxidative phosphorylation system for their own use (Green and... 

Module 3, Column and Mobile Phase Design (CMP). This is the core module for ECAT. It can currently specify i) analytical column and mobile phase constituents for reverse phase chromatography of common classes of organic molecules ii) reverse phase, ion exchange phase and hydrophobic interaction chromatography of proteins and peptides iii) a limited set of specialty classes of molecules best treated by straight phase chromatography (e.g., mono- and disaccharides). The rules for selection of the HPLC detector are under development within Module 3. Some of the rules for detector mobile phase compatibility are already encoded. A set of rules for detector selection is ready but not yet encoded. 

The Role of DPls in Therapy briefly discusses factors affecting the therapeutic profiles of drugs delivered by DPI devices. The article concludes with The Burgeoning DPI Industry, which surveys the DPI products on the market in 1999 and a selection of those known to be under development. Thoughts on the potential of the DPI dosage form in future therapeutic applications conclude the article. 

---